Discover how autoantibodies are transforming prostate cancer detection with unprecedented accuracy, potentially sparing millions from unnecessary invasive procedures.
Discover how ketogenic enzymes become upregulated in aggressive prostate cancer, challenging our understanding of cancer metabolism and opening new diagnostic and therapeutic avenues.
Exploring how proteomics and SILAC technology reveal new biomarkers and treatment targets for castration-resistant prostate cancer.
Discover how ibrutinib, a blood cancer drug, is being repurposed to make prostate cancer responsive to immunotherapy by targeting tumor-infiltrating B cells.